Related Experiment Video
Updated: Jul 19, 2026

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications
Published on: December 8, 2016
hCTLA4-gene modified human bone marrow-derived mesenchymal stem cells as allogeneic seed cells in bone tissue
Fei Dai1, Dongwen Shi, Weifeng He
1Department of Orthopaedics, Southwest Hospital, Chongqing, People's Republic of China.
Abstract:
Immune rejection of heterogeneic seed cells, even of low antigenicity human bone marrow derived mesenchymal stem cells (hBMMSCs), remains an obstacle for bone tissue engineering. It is still a question how to transfer the gene of human cytotoxic T lymphocyte-associated antigen 4-Ig (CTLA4-Ig), a well-known ligand for CD80/CD86, to hBMMSCs to prolong survival time while not interfering with their osteogenesis in vivo. Our data, for the first time, clearly demonstrate that CTLA4-Ig gene modified hBMMSCs could normally differentiate to osteoblasts in vitro, significantly inhibit immune response in the model of mixed lymphocyte culture, and survive until bone tissue formed in vivo. Thus, CTLA4Ig gene-modified hBMMSCs might be promising seed cells for bone tissue engineering.
More Related Videos
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Mesenchymal Stem Cells

